We conclude that targeting the increased metabolic flexibility of cancer cells with tolerance to environmental stress, or of metabolic escape mechanisms ensuring DNA repair and cell survival under therapy, e.g., by pharmacologic inhibition of SLC25A1, represent attractive strategies to enhance vulnerability to genotoxic treatments and overcome microenvironment-mediated resistance to radio(chemo)therapy in advanced cancers. The gene discussed is SLC25A1; the disease is cancer.